
UK - Aquarius Origin invests in Conformetrix
Newly-launched Aquaris Origin Fund has acquired a minority stake in drug development company Conformetrix in a deal of undisclosed value.
Though no financial details have been disclosed, the fund typically invests a maximum of £750,000 at one time.
Manchester-based Conformetrix specialises in analysing natural molecules to help discover new drug treatments. The Manchester University spin-out was founded in 2008 and employs five people.
The Aquarius Origin Fund was launched less than six months ago with the aim of raising £7.5m to invest in high growth potential unlisted companies based predominately in the north of England. Its fund is made up of cash from high net worth individuals.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater